Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature.

ABSTRACT:

Background

Adjuvant chemotherapy (AC) is recommended since 2004 for patients with a completely resected non-small cell lung cancer (NSCLC). Indeed, several randomized clinical trials have demonstrated an improved survival for patients treated with adjuvant cisplatin-based regimen than surgery alone. In these large clinical trials, patients were well selected and fit to receive AC. As the benefit of AC was estimated at 5.4% of 5-year overall survival (OS), it seems important to evaluate AC use in a less selected population. In particular, elderly patients were underrepresented in large randomized clinical trials. Furthermore, other confounding factors might limit AC efficacy in real-life practice such as the delay of chemotherapy initiation following lung surgery or the number of AC

SUBMITTER: Desage AL 

PROVIDER: S-EPMC8743521 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature